CR10024A - Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos - Google Patents

Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos

Info

Publication number
CR10024A
CR10024A CR10024A CR10024A CR10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A CR 10024 A CR10024 A CR 10024A
Authority
CR
Costa Rica
Prior art keywords
egfr
vegf
methods
links
same
Prior art date
Application number
CR10024A
Other languages
English (en)
Spanish (es)
Inventor
Olga Ignatovich
Steve Holmes
Roland Beckmann
Haiqun Liu
Wildt Rudolf M T De
Laurent S Jespers
Michael Steward
Malgorzata Pupecka
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of CR10024A publication Critical patent/CR10024A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CR10024A 2005-12-06 2008-05-27 Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos CR10024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11

Publications (1)

Publication Number Publication Date
CR10024A true CR10024A (es) 2008-09-22

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10024A CR10024A (es) 2005-12-06 2008-05-27 Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos

Country Status (13)

Country Link
US (2) US20100056439A1 (enExample)
EP (1) EP1966242A1 (enExample)
JP (1) JP2009518024A (enExample)
KR (1) KR20080077261A (enExample)
AU (1) AU2006323412A1 (enExample)
BR (1) BRPI0619463A2 (enExample)
CA (1) CA2632417A1 (enExample)
CR (1) CR10024A (enExample)
EA (1) EA013878B1 (enExample)
MA (1) MA30021B1 (enExample)
NO (1) NO20082386L (enExample)
TW (1) TW200804425A (enExample)
WO (1) WO2007066106A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
UY31504A1 (es) * 2007-11-30 2009-07-17 Construcciones de union de antigenos
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CA2718480A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
WO2010033249A2 (en) * 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
WO2010046337A2 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for dc-sign
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
JP5901517B2 (ja) * 2009-05-28 2016-04-13 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合性タンパク質
SG177601A1 (en) * 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EA201390116A1 (ru) * 2010-08-20 2013-09-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Улучшенные связывающие варианты против сывороточного альбумина
EP2853542A1 (en) * 2010-11-24 2015-04-01 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140255471A1 (en) 2013-03-11 2014-09-11 Wake Forest University Health Sciences Method of treating brain tumors
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
CA2974720A1 (en) * 2015-02-06 2016-08-11 University Of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
PL3322734T3 (pl) 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3768722A4 (en) * 2018-03-19 2021-12-29 Wuxi Biologics Ireland Limited. Novel anti-egfr antibody polypeptide
CN113874396B (zh) * 2019-03-29 2024-01-05 株式会社绿十字 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体，及其用途
US12043652B2 (en) 2020-08-28 2024-07-23 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US20060228355A1 (en) * 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Also Published As

Publication number Publication date
CA2632417A1 (en) 2007-06-14
EA013878B1 (ru) 2010-08-30
JP2009518024A (ja) 2009-05-07
MA30021B1 (fr) 2008-12-01
WO2007066106A1 (en) 2007-06-14
US20130041136A1 (en) 2013-02-14
KR20080077261A (ko) 2008-08-21
NO20082386L (no) 2008-08-27
US20100056439A1 (en) 2010-03-04
TW200804425A (en) 2008-01-16
EP1966242A1 (en) 2008-09-10
EA200801172A1 (ru) 2008-12-30
AU2006323412A1 (en) 2007-06-14
BRPI0619463A2 (pt) 2013-01-08

Similar Documents

Publication Publication Date Title
CR10024A (es) Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
GT200600407A (es) Compuestos ppar activos
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
CO6280498A2 (es) Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
ECSP088508A (es) Antagonistas de neuropilina
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
AR066395A1 (es) Reovirus que tienen secuencias modificadas
AR048006A1 (es) CONJUGADOS DE ALMIDON DE HIDROXIALQUILO Y UNA PROTEíNA
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
ECSP099523A (es) Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
DK1951759T3 (da) Anti-EGFR-antistoffer
HN2005029978A (es) Formulaciones
CY1111629T1 (el) Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
AR075896A1 (es) Anticuerpos anti-her (factor de crecimiento epidermico)
ECSP088835A (es) Terapia combinatoria que involucra antagonistas de alfa5beta1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)